Adenocarcinoma of prostate Without Neuroendocrine Differentiation | Adenocarcinoma of prostate Non-small cell
Item
participants who have histologically or cytologically confirm adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
boolean
C0007112 (UMLS CUI [1,1])
C0332288 (UMLS CUI [1,2])
C1709218 (UMLS CUI [1,3])
C0007112 (UMLS CUI [2,1])
C0445128 (UMLS CUI [2,2])
Raised prostate specific antigen Percentage | Status post Antiandrogen Withdrawal
Item
participants who had prostate-specific antigen (psa) progression defined as a rise of psa at least 1 week apart resulting in 25 percent (%) increase in psa with last psa greater than (>) 2 nanogram per milliliter (ng/ml) (according to pcwg2) after antiandrogen withdrawal
boolean
C0178415 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0002842 (UMLS CUI [2,2])
C2349954 (UMLS CUI [2,3])
Raised prostate specific antigen | Status post First line treatment Combined androgen blockade | Prostate specific antigen abnormal During Combined androgen blockade
Item
participants who had psa progression within a year after the start of first-line cab therapy, or who had psa progression without having a normal psa level (less than [<] 4.0 ng/ml) in the first-line combined androgen blockade (cab) therapy
boolean
C0178415 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C3495882 (UMLS CUI [2,3])
C0580555 (UMLS CUI [3,1])
C0347984 (UMLS CUI [3,2])
C3495882 (UMLS CUI [3,3])
Cytotoxic Chemotherapy Absent Prostate carcinoma | Estramustine Absent
Item
participants who have not been treated with cytotoxic chemotherapy (including estramustine) for the treatment of prostate cancer (neoadjuvant or adjuvant chemotherapy is only allowed if the last dose is greater than or equal to [>=] 1 year from the scheduled date of initial administration of abiraterone acetate)
boolean
C0677881 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C0014921 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Target Neoplasm Metastasis Bone scan | Neoplasm Metastasis Non-Target Bone scan | Target Neoplasm Metastasis CT | Neoplasm Metastasis Non-Target CT | Target Neoplasm Metastasis MRI | Neoplasm Metastasis Non-Target MRI
Item
participants who have target or non-target metastatic abnormalities either on screening bone scan, computed tomography (ct) or magnetic resonance imaging (mri)
boolean
C1521840 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0203668 (UMLS CUI [1,3])
C0027627 (UMLS CUI [2,1])
C1518389 (UMLS CUI [2,2])
C0203668 (UMLS CUI [2,3])
C1521840 (UMLS CUI [3,1])
C0027627 (UMLS CUI [3,2])
C0040405 (UMLS CUI [3,3])
C0027627 (UMLS CUI [4,1])
C1518389 (UMLS CUI [4,2])
C0040405 (UMLS CUI [4,3])
C1521840 (UMLS CUI [5,1])
C0027627 (UMLS CUI [5,2])
C0024485 (UMLS CUI [5,3])
C0027627 (UMLS CUI [6,1])
C1518389 (UMLS CUI [6,2])
C0024485 (UMLS CUI [6,3])
Hypersensitivity Abiraterone acetate | Intolerance to Abiraterone acetate | Hypersensitivity Abiraterone acetate Excipient | Intolerance to Abiraterone acetate Excipient
Item
a participant who has known allergies, hypersensitivity, or intolerance to abiraterone acetate or its excipients
boolean
C0020517 (UMLS CUI [1,1])
C2607886 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C2607886 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C2607886 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
C1744706 (UMLS CUI [4,1])
C2607886 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
Liver Dysfunction Severe Child-Pugh Classification | Viral hepatitis | Viral hepatitis Symptomatic | Chronic liver disease
Item
a participant who has severe liver dysfunction (child-pugh score c), active or symptomatic viral hepatitis or chronic liver disease
boolean
C0086565 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C4050412 (UMLS CUI [1,3])
C0042721 (UMLS CUI [2])
C0042721 (UMLS CUI [3,1])
C0231220 (UMLS CUI [3,2])
C0341439 (UMLS CUI [4])
Hormone Therapy | Finasteride Dose Any | Dutasteride Dose Any | Herbal product Decreasing PSA Level | Saw palmetto extract | PC-SPES
Item
a participant who has received other hormonal therapy, including any dose of finasteride, dutasteride, any herbal product known to decrease psa levels (example: saw palmetto and pc-spes) within 4 weeks prior to the scheduled date of initial administration of abiraterone acetate
boolean
C0279025 (UMLS CUI [1])
C0060389 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1552551 (UMLS CUI [2,3])
C0754659 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C1552551 (UMLS CUI [3,3])
C2240391 (UMLS CUI [4,1])
C0442797 (UMLS CUI [4,2])
C4086720 (UMLS CUI [4,3])
C0771607 (UMLS CUI [5])
C0756934 (UMLS CUI [6])
Operative Surgical Procedures | Intervention Prostatic Local
Item
a participant who has had surgery or local prostatic intervention within 4 weeks prior to the scheduled date of initial administration of abiraterone acetate
boolean
C0543467 (UMLS CUI [1])
C0184661 (UMLS CUI [2,1])
C1522721 (UMLS CUI [2,2])
C0205276 (UMLS CUI [2,3])
Communicable Disease | Other medical condition Prednisolone Contraindicated
Item
a participant who has active infection or other medical condition that would make prednisolone use contraindicated
boolean
C0009450 (UMLS CUI [1])
C3843040 (UMLS CUI [2,1])
C0032950 (UMLS CUI [2,2])
C1444657 (UMLS CUI [2,3])